Skip to content
Sign in
Artwork for The Readout Loud
The Readout Loud · April 30 · 41 min

399: Hair-raising trial results, and Servier’s M&A wishlist

Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.

0:00-41:26
Play in

transcript

No transcript — this publisher did not publish one.

show notes

Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena?


We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals.

more episodes

All episodes